參考文獻 |
1 Kovesdy, C. P. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements 12, 7-11, doi:https://doi.org/10.1016/j.kisu.2021.11.003 (2022).
2 Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392, 2052-2090, doi:10.1016/S0140-6736(18)31694-5 (2018).
3 Tsai, H. J., Wu, P. Y., Huang, J. C. & Chen, S. C. Environmental Pollution and Chronic Kidney Disease. Int J Med Sci 18, 1121-1129, doi:10.7150/ijms.51594 (2021).
4 Chen, Y. C. et al. Genome-Wide Association Study for eGFR in a Taiwanese Population. Clin J Am Soc Nephrol 17, 1598-1608, doi:10.2215/CJN.02180222 (2022).
5 Collins, A. J. et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 63, A7, doi:10.1053/j.ajkd.2013.11.001 (2014).
6 DeFronzo, R. A. & Bakris, G. L. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab 24, 1197-1205, doi:10.1111/dom.14696 (2022).
7 Muntner, P. et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 55, 441-451, doi:10.1053/j.ajkd.2009.09.014 (2010).
8 Ceja-Galicia, Z. A. et al. The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids. Foods 12, doi:10.3390/foods12050921 (2023).
9 Wang, M., Lin, X., Yang, X. & Yang, Y. Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease. Ren Fail 44, 615-624, doi:10.1080/0886022X.2022.2036620 (2022).
10 Yamamoto, R. et al. A Dose-Dependent Association between Alcohol Consumption and Incidence of Proteinuria and Low Glomerular Filtration Rate: A Systematic Review and Meta-Analysis of Cohort Studies. Nutrients 15, doi:10.3390/nu15071592 (2023).
11 Seidu, S. et al. Physical activity and risk of chronic kidney disease: systematic review and meta-analysis of 12 cohort studies involving 1,281,727 participants. Eur J Epidemiol 38, 267-280, doi:10.1007/s10654-022-00961-7 (2023).
12 Lamb, E. J., Levey, A. S. & Stevens, P. E. The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution. Clin Chem 59, 462-465, doi:10.1373/clinchem.2012.184259 (2013).
13 Kraus, M. A., Kalra, P. A., Hunter, J., Menoyo, J. & Stankus, N. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: a cross-sectional observational study. Ther Adv Chronic Dis 6, 84-96, doi:10.1177/2040622315578654 (2015).
14 Zhu, H. et al. Machine Learning for the Prevalence and Severity of Coronary Artery Calcification in Nondialysis Chronic Kidney Disease Patients: A Chinese Large Cohort Study. J Thorac Imaging 37, 401-408, doi:10.1097/RTI.0000000000000657 (2022).
15 Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P. & Magnusson, P. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nature Reviews Nephrology 13, 429-442, doi:10.1038/nrneph.2017.60 (2017).
16 Sarnak, M. J. et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 74, 1823-1838, doi:10.1016/j.jacc.2019.08.1017 (2019).
17 Foley, R. N. & Parfrey, P. S. Cardiovascular disease and mortality in ESRD. J Nephrol 11, 239-245 (1998).
18 Matsushita, K. et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol 18, 696-707, doi:10.1038/s41581-022-00616-6 (2022).
19 Matsushita, K., Ballew, S. H. & Coresh, J. Cardiovascular risk prediction in people with chronic kidney disease. Curr Opin Nephrol Hypertens 25, 518-523, doi:10.1097/MNH.0000000000000265 (2016).
20 Ogata, H. et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA 325, 1946-1954, doi:10.1001/jama.2021.4807 (2021).
21 Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32, S112-119, doi:10.1053/ajkd.1998.v32.pm9820470 (1998).
22 Lau, W. L., Festing, M. H. & Giachelli, C. M. Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 104, 464-470, doi:10.1160/TH09-12-0814 (2010).
23 Strauss, H. W., Nakahara, T., Narula, N. & Narula, J. Vascular calcification: the evolving relationship of vascular calcification to major acute coronary events. Journal of Nuclear Medicine 60, 1207-1212 (2019).
24 Jablonski, K. L. & Chonchol, M. Vascular calcification in end-stage renal disease. Hemodial Int 17 Suppl 1, S17-21, doi:10.1111/hdi.12084 (2013).
25 Yin, L. et al. Role of gut microbiota-derived metabolites on vascular calcification in CKD. J Cell Mol Med 25, 1332-1341, doi:10.1111/jcmm.16230 (2021).
26 Lynch, S. V. & Pedersen, O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med 375, 2369-2379, doi:10.1056/NEJMra1600266 (2016).
27 Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65, doi:10.1038/nature08821 (2010).
28 Korem, T. et al. Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science 349, 1101-1106, doi:10.1126/science.aac4812 (2015).
29 Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210-215, doi:10.1038/nature25973 (2018).
30 Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635-1638, doi:10.1126/science.1110591 (2005).
31 Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180, doi:10.1038/nature09944 (2011).
32 Moore, W. E. & Holdeman, L. V. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 27, 961-979, doi:10.1128/am.27.5.961-979.1974 (1974).
33 Mizrahi-Man, O., Davenport, E. R. & Gilad, Y. Taxonomic classification of bacterial 16S rRNA genes using short sequencing reads: evaluation of effective study designs. PLoS One 8, e53608, doi:10.1371/journal.pone.0053608 (2013).
34 Luo, D. et al. The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses. Front Cell Infect Microbiol 11, 579386, doi:10.3389/fcimb.2021.579386 (2021).
35 Dai, L. et al. Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction? Toxins (Basel) 12, doi:10.3390/toxins12060351 (2020).
36 Witkowski, M., Weeks, T. L. & Hazen, S. L. Gut Microbiota and Cardiovascular Disease. Circ Res 127, 553-570, doi:10.1161/CIRCRESAHA.120.316242 (2020).
37 Spychala, M. S. et al. Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome. Ann Neurol 84, 23-36, doi:10.1002/ana.25250 (2018).
38 Tanase, D. M. et al. Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM). Nutrients 12, doi:10.3390/nu12123719 (2020).
39 Onal, E. M., Afsar, B., Covic, A., Vaziri, N. D. & Kanbay, M. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. Hypertens Res 42, 123-140, doi:10.1038/s41440-018-0144-z (2019).
40 Velasquez, M. T., Centron, P., Barrows, I., Dwivedi, R. & Raj, D. S. Gut Microbiota and Cardiovascular Uremic Toxicities. Toxins (Basel) 10, doi:10.3390/toxins10070287 (2018).
41 Shin, N. R., Whon, T. W. & Bae, J. W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 33, 496-503, doi:10.1016/j.tibtech.2015.06.011 (2015).
42 Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Applied and environmental microbiology 75, 7537-7541 (2009).
43 Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79, 5112-5120, doi:10.1128/AEM.01043-13 (2013).
44 Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194-2200, doi:10.1093/bioinformatics/btr381 (2011).
45 Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41, D590-596, doi:10.1093/nar/gks1219 (2013).
46 Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods 7, 335-336 (2010).
47 Oksanen, J. et al. Vegan: community ecology package http://CRAN. R-project. org/package= vegan (2013).
48 Warnes, G. R. et al. gplots: Various R programming tools for plotting data. R package version 2, 1 (2009).
49 Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol 12, R60, doi:10.1186/gb-2011-12-6-r60 (2011).
50 Jonsson, V., Osterlund, T., Nerman, O. & Kristiansson, E. Statistical evaluation of methods for identification of differentially abundant genes in comparative metagenomics. BMC Genomics 17, 78, doi:10.1186/s12864-016-2386-y (2016).
51 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186/s13059-014-0550-8 (2014).
52 Langille, M. G. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature biotechnology 31, 814-821 (2013).
53 Bao, W. H. et al. Relationship between gut microbiota and vascular calcification in hemodialysis patients. Ren Fail 45, 2148538, doi:10.1080/0886022X.2022.2148538 (2023).
54 Merino-Ribas, A. et al. Vascular Calcification and the Gut and Blood Microbiome in Chronic Kidney Disease Patients on Peritoneal Dialysis: A Pilot Study. Biomolecules 12, doi:10.3390/biom12070867 (2022).
55 Sumida, K., Yamagata, K. & Kovesdy, C. P. Constipation in CKD. Kidney Int Rep 5, 121-134, doi:10.1016/j.ekir.2019.11.002 (2020).
56 Chung, S., Barnes, J. L. & Astroth, K. S. Gastrointestinal Microbiota in Patients with Chronic Kidney Disease: A Systematic Review. Adv Nutr 10, 888-901, doi:10.1093/advances/nmz028 (2019).
57 Liu, S. et al. Effect of probiotics on the intestinal microbiota of hemodialysis patients: a randomized trial. Eur J Nutr 59, 3755-3766, doi:10.1007/s00394-020-02207-2 (2020).
58 Ren, Z. et al. Alterations of the Human Gut Microbiome in Chronic Kidney Disease. Adv Sci (Weinh) 7, 2001936, doi:10.1002/advs.202001936 (2020).
59 Wu, I.-W. et al. Gut microbiota as diagnostic tools for mirroring disease progression and circulating nephrotoxin levels in chronic kidney disease: discovery and validation study. International journal of biological sciences 16, 420 (2020).
60 De Angelis, M. et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9, e99006, doi:10.1371/journal.pone.0099006 (2014).
61 Vaziri, N. D. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83, 308-315, doi:10.1038/ki.2012.345 (2013).
62 Joffe, Y. T., Collins, M. & Goedecke, J. H. The relationship between dietary fatty acids and inflammatory genes on the obese phenotype and serum lipids. Nutrients 5, 1672-1705, doi:10.3390/nu5051672 (2013).
63 Matsumoto, N. et al. Relationship between Nutrient Intake and Human Gut Microbiota in Monozygotic Twins. Medicina (Kaunas) 57, doi:10.3390/medicina57030275 (2021).
64 Ferguson, J. F. et al. High dietary salt-induced dendritic cell activation underlies microbial dysbiosis-associated hypertension. JCI Insight 5, doi:10.1172/jci.insight.126241 (2019).
65 Seldin, M. M. et al. Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB. J Am Heart Assoc 5, doi:10.1161/jaha.115.002767 (2016).
66 Gao, J. et al. Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events. Scientific Reports 10, 2639, doi:10.1038/s41598-020-59235-5 (2020).
67 Vojinovic, D. et al. Relationship between gut microbiota and circulating metabolites in population-based cohorts. Nat Commun 10, 5813-5813, doi:10.1038/s41467-019-13721-1 (2019).
68 Tang, C. et al. Effects of polysaccharides from purple sweet potatoes on immune response and gut microbiota composition in normal and cyclophosphamide treated mice. Food Funct 9, 937-950, doi:10.1039/c7fo01302g (2018).
69 Zou, X. Y. et al. Bacillus subtilis inhibits intestinal inflammation and oxidative stress by regulating gut flora and related metabolites in laying hens. Animal 16, 100474, doi:10.1016/j.animal.2022.100474 (2022).
70 Jovanovich, A., Isakova, T. & Stubbs, J. Microbiome and Cardiovascular Disease in CKD. Clin J Am Soc Nephrol 13, 1598-1604, doi:10.2215/CJN.12691117 (2018).
71 Gupte, S. A. et al. Vascular Signaling by Free Radicals Pentose phosphate pathway coordinates multiple redox-controlled relaxing mechanisms in bovine coronary arteries. Am J Physiol Heart Circ Physiol 285, H2316-H2326 (2003).
72 Peiró, C. et al. Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovascular diabetology 15, 1-15 (2016).
73 Zhu, Y. et al. Advanced glycation end products accelerate calcification in VSMCs through HIF-1α/PDK4 activation and suppress glucose metabolism. Scientific reports 8, 1-12 (2018).
74 Colhoun, H. M. et al. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 51, 1949-1956 (2002).
75 Prenner, S. B. et al. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis 236, 244-250, doi:10.1016/j.atherosclerosis.2014.07.008 (2014).
76 Xie, X. et al. Association of very low-density lipoprotein cholesterol with all-cause and cardiovascular mortality in peritoneal dialysis. Kidney and Blood Pressure Research 42, 52-61 (2017).
77 Ren, J. et al. Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). Atherosclerosis 211, 327-332, doi:10.1016/j.atherosclerosis.2010.02.020 (2010).
78 Aarsland, A. & Wolfe, R. R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res 39, 1280-1286 (1998).
79 Kageyama, A. et al. Palmitic acid induces osteoblastic differentiation in vascular smooth muscle cells through ACSL3 and NF-κB, novel targets of eicosapentaenoic acid. PLoS One 8, e68197 (2013).
80 Huang, J. M., Xian, H. & Bacaner, M. Long-chain fatty acids activate calcium channels in ventricular myocytes. Proceedings of the National Academy of Sciences of the United States of America 89, 6452-6456, doi:10.1073/pnas.89.14.6452 (1992).
81 Liu, T. et al. Bioaccumulation of blood long-chain fatty acids during hemodialysis. Metabolites 12, 269 (2022).
82 Block, G. A., Kilpatrick, R. D., Lowe, K. A., Wang, W. & Danese, M. D. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 8, 2132-2140, doi:10.2215/CJN.04260413 (2013).
83 Danese, M. D., Belozeroff, V., Smirnakis, K. & Rothman, K. J. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 3, 1423-1429, doi:10.2215/CJN.01060308 (2008).
84 Viegas, C., Araújo, N., Marreiros, C. & Simes, D. The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts. Aging (Albany NY) 11, 4274 (2019). |